3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
AstraZeneca Pharma India's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 13.45%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for AstraZeneca Pharma India's 3-Year ROIIC % or its related term are showing as below:
NSE:ASTRAZEN's 3-Year ROIIC % is ranked better than 64.19% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs NSE:ASTRAZEN: 13.45
AstraZeneca Pharma India (NSE:ASTRAZEN) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
AstraZeneca Pharma India 3-Year ROIIC % Related Terms
AstraZeneca Pharma India 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTRAZEN vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a 3-Year ROIIC % of 13.45 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on AstraZeneca Pharma India and its competitors. This is 66% below median its historical median of 39.42. According to the industry distribution chart, AstraZeneca Pharma India ranks #338 out of 944 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is AstraZeneca Pharma India's 3-Year ROIIC % too high?
AstraZeneca Pharma India's current 3-Year ROIIC % of 13.45 is 66% below median its 10-year median of 39.42. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. AstraZeneca Pharma India's value of 13.45 is 270% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #338 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #338 out of 944 companies for 3-Year ROIIC %. This puts AstraZeneca Pharma India in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. AstraZeneca Pharma India's value of 13.45 is 270% above this benchmark. While the company's 10-year median is 39.42 vs. the industry median of 3.64, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current 3-Year ROIIC % of 13.45 is 270% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current 3-Year ROIIC % is 13.45, which is 66% below median its own 10-year median of 39.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,953.84, compared to a current price of ₹8,117.50 — trading 25.9% below its estimated fair value. The current 3-Year ROIIC % is 13.45, which is 66% below median its 10-year median of 39.42 and 270% above the Drug Manufacturers industry median of 3.64. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current 3-Year ROIIC % is 13.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,117.50 is trading 25.9% below its estimated GF Value™ of ₹10,953.84.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
3-Year ROIIC %: 13.45 (66% below median its 10-year median of 39.42)
GF Value™: ₹10,953.84 vs. price of ₹8,117.50 (25.9% below fair value)
Industry Position: 270% above the Drug Manufacturers median (#338 of 944)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
